Sumitomo Pharma Co (STU:DPM) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:DPM Sumitomo Pharma Co Ltd STU:DPM
71 GF Score
Price €6.46
GF Value €4.66
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Sumitomo Pharma Co FFO?

FFO (Funds from operations) only applies to REITs.

STU:DPM
71GF Score
Sumitomo Pharma Co Ltd STU:DPM
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Sumitomo Pharma Co (STU:DPM) Overvalued in 2026?

Based on GuruFocus' analysis, Sumitomo Pharma Co stock appears to be overvalued. The current stock price of €6.46 is trading 38.6% above its estimated GF Value™ of €4.66. GuruFocus considers Sumitomo Pharma Co to be Significantly Overvalued.

Key valuation signals for STU:DPM:

  • FFO:
  • GF Value™: €4.66 vs. price of €6.46 (38.6% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the STU:DPM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sumitomo Pharma Co Business Description

Address 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, JPN, 541-0045
Sumitomo Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business. The pharmaceutical business maintains a focus on a variety of areas, including cardiovascular/diabetes, psychiatry & neurology, and specialty areas. Sumitomo considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
71GF Score

Get the complete analysis for STU:DPM

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.46
Price
€4.66
GF Value